Can we trust the quality of pharmaceuticals?

An exploration into the science, regulation, consequences, and future of drug quality in the US.

Quality deficiencies in the drug supply chain, sometimes resulting in large-scale drug recalls, have captured headlines in the US in recent years. Such events can erode public trust in pharmaceutical products, including generics, which account for more than 90% of all medications dispensed in the US. 

But are the quality issues featured in the media widespread, or are they unfortunate one-off events driven by bad actors in the system? 

The 2021 Pharmaceutical Outcomes and Policy Seminar will examine the complex and interrelated scientific, regulatory, supply chain, and system factors that underpin drug supply and utilization in the US. Experts will explain the challenges they face in ensuring that patients have access to pharmaceutical products that are safe and effective and of high quality. Participants will consider the implications of potential erosion in generic drug utilization on patient outcomes and costs. Finally, industry leaders will pose regulatory, delivery, and commercial solutions to improve the quality of the drug supply chain. 

Speakers to be announced.

Student Requirements

1. Attend and participate in all Zoom sessions
2. Complete required readings (text and supplementary)
3. Complete pre-seminar assignment on Canvas
4. Complete post-seminar assignment on Canvas

Questions

Feel free to contact either Heather Steingraber or Laura Happe with any questions related to Seminar Weekend.

2020 Seminar Highlights

The 2020 seminar took place on March 7-8 and focused on real-world evidence.